A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

NCT01718145 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: Daclatasvir
DRUG: Asunaprevir
DRUG: Ribavirin
BIOLOGICAL: pegIFNα-2b
DRUG: Telaprevir

Sponsor

Bristol-Myers Squibb